# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-25T13:12:25.149429
**Route:** OpenRouter + LaTeX
**Paper Hash:** bc7ef958da6fb2b8
**Tokens:** 17227 in / 1907 out
**Response SHA256:** 209dbb5405f4d7b9

---

No fatal errors detected in the four categories you specified. The empirical designs appear feasible with the stated data coverage; regression outputs look numerically sane; tables include Ns and SEs; and I did not find placeholders like “TBD/NA/XXX” in places where results are required.

A few **non-fatal but “check before submission”** items (not grounds for FAIL under your rules, but worth verifying to avoid later confusion):

- **Minamata cohort-year terminology:** In the CS-DiD description you say “treatment cohorts spanning 2015–2022,” while Table `tab:ratification` lists ratification years starting in 2014. This is consistent *if* cohorts are defined by **first treated year (ratification year + 1)** rather than ratification year itself. Consider aligning the terminology everywhere (e.g., explicitly say “cohorts by first treated year” in the CS-DiD section).
- **Sample-size arithmetic in Minamata Table (5):** Note says dropping 2011 reduces N from 1,003 to 972 (drop of 31). That is possible if only 31 observations exist in 2011 in the regression sample due to missing outcomes, but it’s worth confirming so it doesn’t look like a mistake to readers.

## Checklist against your fatal-error criteria

### 1) Data–Design Alignment (critical)
- **Treatment timing vs data coverage:**  
  - EU ban (2011; post defined as ≥2012) is within data (2000–2023).  
  - Minamata: you explicitly code 2023–2024 ratifiers as untreated due to no/full limited post period through 2023; this avoids the classic “treated after data ends” misalignment.
- **Post-treatment observations:**  
  - EU ban design has post years (2012–2015 baseline; more in robustness).  
  - CS-DiD: cohorts are restricted to those with at least one post-treatment year (ratified by 2022 ⇒ first treated year 2023). That yields at least one post year, as stated.
- **Treatment definition consistency:** No direct contradiction found between the written definition (“first full calendar year after ratification”) and how the cohorts are described, though see the non-fatal terminology note above.

### 2) Regression Sanity (critical)
Scanned all reported regression tables:
- **SEs:** No implausibly huge SEs (nothing like SE>1000; nothing like SE>100×|coef|).
- **Coefficients:** No impossible magnitudes (no |coef|>100; log outcomes not showing extreme >10 magnitudes).
- **Impossible values:** All R² are in [0,1]; no NA/NaN/Inf shown; no negative SEs.

### 3) Completeness (critical)
- Regression tables report **Num.Obs.** and include **standard errors**.
- Methods described (EU DiD, event study, CS-DiD) have corresponding results shown (tables/figures and appendix ATT table).
- No “TODO/TBD/XXX” placeholders in results tables.

### 4) Internal Consistency (critical)
- Key headline numbers in text match the corresponding tables (e.g., EU ban coefficient −2.464 SE 0.980 in Table `tab:eu_ban`; Minamata TWFE 2.585 SE 0.669 in Table `tab:minamata`; CS overall ATT −1.6406 SE 1.6770 in Table `tab:cs_att`).
- Sample-window statements are arithmetically plausible (e.g., EU: 54 countries × 10 years = 540).

ADVISOR VERDICT: PASS